Making it in NYC: a Little Luck & a lot of Grit

Add this event to your calendar:
15/03/2018 16:30 15/03/2018 19:00 America/New_York Making it in NYC: a Little Luck & a lot of Grit New York Genome Center , 101 6th Ave. , New York , New York 10013 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY
March
15
Event

Making it in NYC: a Little Luck & a lot of Grit

New York Genome Center , 101 6th Ave. , New York , New York 10013

March 15, 2018 from 16:30 PM to 19:00 PM (EST)

$10 - $35


The road to success in the concrete jungle is a long one with no guarantees, especially when it comes to the start-up space. There are many factors to success, skill, determination, money, the right team…some may even say the biggest factor is luck. Join us as we examine just how much luck is involved in turning one idea into a tangible innovative product, solution or business.
At JLABS @ NYC, we invite you to a fireside chat with founders who have been there before and can shine a light on what it really takes to build a company from the ground up. Spoiler alert: it takes a little more hustle and determination than “luck of the draw”!

Moderator:
Jeremy A. Abbate | VP & Publisher, Scientific American  read bio»

Participating Representatives:
Cristina Dolan | Co-Founder & COO, IxLedger read bio»
Maria Luisa Pineda | Co-Founder and CEO, Envisagenics, Inc, read bio»


Agenda:
03:30 PM | Registration Opens and Networking
04:00 PM | Fireside Chat and Q&A
05:00 PM | Networking Session
06:00 PM | Program Close


Fees:

Presentation & Lunch
$25 | General Public
$35 | At the door
Includes presentation, Q&A, and refreshments.

Venue:
New York Genome Center
101 6th Ave.
New York, NY 10013
Map it


Speakers' Biographies:

Jeremy A. Abbate | VP & Publisher, Scientific American 

He is responsible for developing and executing new media programs, brand extensions and collaborative ventures serving the international opinion leadership that turns to Scientific American and its related titles for the best views of the future.
As the founder of Scientific American’s Worldview enterprise, a global exploration of health and life science innovation produced in collaboration with the Biotechnology Innovation Organization, he leads the teams that create its content, distribution network and visibility platforms for its sponsors.
He has made many appearances at conferences and events to facilitate high-level discussions on innovative science and technology. He has spearheaded co-branded partnerships with several international organizations including TEDMED, CES, the Bill & Melinda Gates Foundation, OSU’s Brain Health Summit and The Carter Center. Working to bring important scientific ideas into a dynamic media environment, he has led projects serving some of the world’s largest corporate organizations, including Colgate Palmolive, Johnson& Johnson, Procter & Gamble, Philips, Life Technologies, Amgen, Caterpillar and Celgene.
Additionally, he leads several content and product initiatives at Scientific American that serve the educational and STEM markets.
His writing has appeared in The Wall Street Journal, Forbes, Patients Beyond Borders, McSweeney’s, and other national publications.
Abbate was previously the Director of New Business for The Scientist magazine, a media entity servicing working scientists and industry leaders. He serves on the advisory board for The Global Wellness Institute.

Cristina Dolan | Co-Founder & COO, IxLedger

Cristina Dolan is Co-Founder and COO of iXledger an alternative marketplace for insurance based on blockchain. As a former executive at a software company that offers award winning global multi-asset institutional trading solutions in the cloud, she is applying her knowledge of traditional marketplaces to the creation of next generation blockchain enabled marketplaces in combination with advanced technologies through digital transformation to create efficiencies and opportunities.
Internet Pioneer and MIT Media Lab alumna, Cristina, co-founded OneMain, which grew to be the 10 largest Internet Service Provider. The company was later acquired by Earthlink after a highly successful initial public offering. At Hearst and Disney she headed up technology and built the first consumer internet websites. In addition to executive roles at IBM and Oracle bringing new products to market, Cristina was CEO of venture backed MIT spinoff Wordstream.
As an engineer, computer scientist, futurist and solutionist, Cristina appreciates the value of applying engineering skills to problem solving, which was the topic of her TEDx talk “Just Solve It”. In 2013 she launched the global student competition “Dream it. Code it. Win it.” which has been honored with; a Trader Magazine Charitable Contribution Award, a MIT Harold E. Lobdell Distinguished Service Award and four Stevie Awards for Best Organization, Best Female Innovator and Best Executive of the Year. Currently, Cristina serves as the MIT Enterprise Forum of NYC Vice Chair.
Cristina earned a Master’s Degree from the MIT Media Lab and holds a Master of Computer Science and Bachelors of Electrical Engineering with concentrations in Computer Science, Data Communications and Business. She was a member of the US Bobsled and Skeleton team, earned first place in US Nationals and Empire State Games. She placed second for women at the Skeleton World Cup Championship. Fluent in Castilian Spanish in addition to her native language, English.

.

Maria Luisa Pineda Ph.D.| Co-Founder and CEO, Envisagenics, Inc

Dr. Maria Luisa Pineda is the co-founder and CEO of Envisagenics, Inc. a biotech spinout of Cold Spring Harbor Laboratory that has developed a machine learning platform to predict disease-causing aberrant splicing through the analysis of massive amounts of RNA-seq data. With this platform, Envisagenics will identify biologically relevant and druggable targets and design RNA-therapeutics that will be validated in preclinical and clinical studies.
Dr. Pineda received her PhD from the prestigious Watson School of Biological Sciences at Cold Spring Harbor Laboratory, then she acquired investment experience in technology and life-science startup companies at Canrock Ventures and Golden Seeds, LLC. Under Dr. Pineda’s leadership, Envisagenics has acquired funding from the National Institutes of Health Small Business Innovation Research (SBIR) program and pre-seed investments from Topspin Partners and the Long Island Emerging Technology Fund, and from Breakout Labs, a Peter Thiel foundation. Envisagenics also closed a $2.35M seed round backed by Third Kind Venture Capital (3KVC), Cosine, LLC (NYC biotech investors), Dolby Family Ventures, Dynamk Capital, NY Empire State Development (ESD), and SV Angel. Most recently, Envisagenics was selected as a winner of JLABS Artificial Intelligence for Drug Discovery QuickFire Challenge. Dr. Pineda has been named one of the top 20 Latinas in NYC by El Diario, NYC’s oldest Spanish Language newspaper and was selected for the Stanford Latino Entrepreneur Leaders Program developed by the Latino Business Action Network and the Stanford Graduate School of Business. .


Johnson & Johnson Innovation, JLABS

  About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com or follow @JNJInnovation.

Event contact


Related content